canada clinical guidance

Spondyloarthritis: diagnosis and management

A Canadian clinical summary of spondyloarthritis: diagnosis and management, with source-attributed priorities and explicit jurisdiction boundaries.

JurisdictionCanada
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceHealthcare professionals practising in Canada
This is an iatroX educational summary of named Canada sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.

Source and scope

This summary is bounded to the recommendations, population and decisions covered by Living Guideline for the Management of Axial Spondyloarthritis: April 2026 update. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:CRA/SPARCC axSpA 2026

Source-attributed clinical priorities

  • Recognize inflammatory back pain, enthesitis, dactylitis, uveitis, psoriasis and inflammatory bowel disease associations.
  • Do not exclude axial spondyloarthritis solely because inflammatory markers, HLA-B27 or plain radiographs are normal.
  • Refer suspected inflammatory disease for rheumatology assessment and maintain exercise and cardiovascular-risk care.
  • Ask about uveitis, psoriasis, inflammatory bowel disease and family history because extra-articular clues support recognition.
sources for this section:CRA/SPARCC axSpA 2026

Practical assessment and management workflow

1
Characterize morning stiffness, night pain, exercise response, enthesitis, dactylitis and peripheral synovitis.
2
Examine spine mobility, sacroiliac provocation, entheses, joints, skin, nails and eyes.
3
Order inflammatory markers and appropriate pelvic imaging without using normal results to exclude early disease.
4
Refer suspected axial or peripheral inflammatory disease and track activity, function and treatment toxicity.
sources for this section:CRA/SPARCC axSpA 2026

Safety, red flags and urgent escalation

  • A painful red photophobic eye requires urgent ophthalmic assessment for uveitis.
  • Escalate acute neurologic compromise or possible spinal fracture, especially in an ankylosed spine.
  • Screen infection and update vaccination before biologic or targeted immunomodulatory therapy.
sources for this section:CRA/SPARCC axSpA 2026

Confirm the local pathway before acting

The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:CRA/SPARCC axSpA 2026

Source and implementation boundary

Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:CRA/SPARCC axSpA 2026

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Canadian Rheumatology Association and Spondyloarthritis Research Consortium of CanadaLiving Guideline for the Management of Axial Spondyloarthritis: April 2026 updateLiving guideline update 1; April 2026 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Found a source update or regional discrepancy? Tell the iatroX editorial team.